Press Releases Astellas Pharma Inc. OTC Markets

Equities

ALPMY

US04623U1025

Market Closed - OTC Markets Other stock markets 03:59:59 2024-07-12 pm EDT			5-day change	1st Jan Change
10.46 ^USD	+1.26%		+4.39%	-12.10%

Jul. 02	Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer	CI
Jun. 03	US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Astellas Confirms Unfavorable District Court Decision Concerning its Motion for a Preliminary Injunction against Lupin and Zydus Generic Versions of MyrbetriqTM	Apr. 23	AQ
U.S. FDA Accepts Astellas' Supplemental New Drug Application for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy	Apr. 04	AQ
Astellas VYLOY Approved in Japan for Treatment of Gastric Cancer	Mar. 27	AQ
Iveric Bio - Astellas Receives Permanent J-code for IZERVAY for Geographic Atrophy	Mar. 27	AQ
Astellas Receives Positive CHMP Opinion for XTANDI in Additional Recurrent Early Prostate Cancer Treatment Setting	Mar. 25	AQ
Xyphos Biosciences enters research collaboration and license agreement with Kelonia Therapeutics	Feb. 16	AQ
Astellas Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer	Jan. 31	AQ
Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager	Dec. 27	BU
Pfizer Inc. - PADCEV with KEYTRUDA Approved by FDA as the First and Only ADC plus PD-1 to Treat Advanced Bladder Cancer	Dec. 18	AQ
Astellas Pharma Inc. - PADCEV with KEYTRUDA Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer	Dec. 18	AQ
Astellas Pharma Inc. - EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children	Dec. 18	AQ
Astellas secures EC approval for VMS treatment, fezolinetant	Dec. 14	AQ
Astellas VEOZA Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause	Dec. 11	AQ
Outgoing Japan envoy regrets not being able to rescue detained man	Dec. 04	AQ
Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies	Dec. 01	AQ
Astellas Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy	Nov. 30	AQ
Japan envoy meets citizen detained in China over spying for 1st time	Nov. 28	AQ
Astellas Pharma Inc. - University of Tsukuba and Astellas Confirm a Strategic Partnership	Nov. 17	AQ
Pfizer and Astellas XTANDI Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting	Nov. 17	AQ
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug for Systemic Oncolytic Virus ASP1012 for Phase I Clinical Trials for Locally Advanced or Metastatic Solid Tumors	23-10-25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Astellas Pharma Inc. OTC Markets

Equities

ALPMY

US04623U1025

Press Releases

Filters